Resolution of the National Multidisciplinary Research Council of Experts on the place of anti-interleukin-6 receptor monoclonal antibodies (Sarilumab) in the treatment of patients with rheumatoid arthritis and comorbidity

Resolution of the National Multidisciplinary Research Council of Experts on the place of anti-interleukin-6 receptor monoclonal antibodies (Sarilumab) in the treatment of patients with rheumatoid arthritis and comorbidity

.

Bibliographic Details
Main Author:	article Editorial
Format:	Article
Language:	Russian
Published:	IMA-PRESS LLC 2020-06-01
Series:	Научно-практическая ревматология
Online Access:	https://rsp.mediar-press.net/rsp/article/view/2905

Similar Items

The efficacy and safety of sarilumab, fully human monoclonal antibodies against interleukin 6 receptor, in rheumatoid arthritis: new evidence
by: E. L. Nasonov, et al.
Published: (2019-11-01)

Inhibitor of biological effects of interleukin-6 sarilumab in treatment of rheumatoid arthritis
by: D. E. Karateev, et al.
Published: (2019-12-01)

Sarilumab: patient-reported outcomes in rheumatoid arthritis
by: Crotti C, et al.
Published: (2018-08-01)

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis
by: Raimondo MG, et al.
Published: (2017-05-01)

New possibilities of drug therapy for rheumatoid arthritis: focus at sarilumab
by: D. E. Karateev, et al.
Published: (2019-11-01)

Resolution of the Research Council of Experts on the place of netakimab, a new interleukin-17a inhibitor, in the therapy of ankylosing spondylitis
by: article Editorial
Published: (2020-06-01)

Resolution of the council of experts “Papillomavirus infection: the review of accumulated experience in the decision of multidisciplinary problem”
by: Article Editorial
Published: (2019-02-01)

Resolution of the Scientific Council of Experts: “The place of netakimab, a new inhibitor of IL-17A, in the treatment of psoriatic arthritis
by: article Editorial
Published: (2020-09-01)

Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open‐Label Extension of a Randomized Clinical Trial
by: Paul Emery, et al.
Published: (2020-11-01)

Combination Therapy with Nintedanib and Sarilumab for the Management of Rheumatoid Arthritis Related Interstitial Lung Disease
by: Caterina Vacchi, et al.
Published: (2020-01-01)

Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis
by: Pelechas E, et al.
Published: (2019-09-01)

High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab
by: Vibeke Strand, et al.
Published: (2020-10-01)

Expert Council Resolution «Human Papillomavirus Infection: a Review of Experience in Solving a Multidisciplinary Problem»
by: article Editorial
Published: (2019-01-01)

Prospects of pharmacotherapy for rheumatoid arthritis: Monoclonal antibodies
by: Evgeny Lvovich Nasonov, et al.
Published: (2012-06-01)

New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)
by: Evgeniy L'vovich Nasonov, et al.
Published: (2010-05-01)

Resolution of the Expert Council on Osteoarthritis (January 19, 2019)
by: article Editorial
Published: (2019-05-01)

COMORBIDITY IN RHEUMATOID ARTHRITIS
by: T. A. Panafidina, et al.
Published: (2014-06-01)

Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs
by: Alvin F. Wells, et al.
Published: (2019-05-01)

Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis
by: Pavel Kovalenko, et al.
Published: (2020-07-01)

The Resolution of the Meeting of Expert Council on Pneumococcal Disease and Vaccination in Russia
by: Editorial Article
Published: (2017-02-01)

Administration of monoclonal antibodies to b-lymphocytes (rituximab) in rheumatoid arthritis in Russia
by: E L Nasonov, et al.
Published: (2008-08-01)

Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies
by: Ferrufino CP, et al.
Published: (2018-11-01)

COMORBIDITY IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: N. M. Nikitina, et al.
Published: (2015-04-01)

National Rheumatology Summit. Place of adalimumab in current pharmacotherapy strategy for rheumatoid arthritis
by: Article Editorial
Published: (2015-09-01)

Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis
by: Vibeke Strand, et al.
Published: (2018-06-01)

Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies [Corrigendum]
by: Ferrufino CP, et al.
Published: (2019-01-01)

Interleukin-6 in Rheumatoid Arthritis
by: Franco Pandolfi, et al.
Published: (2020-07-01)

Interleukin 6 and Rheumatoid Arthritis
by: Yuji Yoshida, et al.
Published: (2014-01-01)

RESOLUTION OF THE NATIONAL SCIENTIFIC COUNCIL OF EXPERTS "THE OPTIONS OF INCREASING REMISSION IN PATIENTS WITH PARTIAL EPILEPSY"
by: Editorial article
Published: (2017-11-01)

Expert Council resolution on the specifics of multiple myeloma therapy during COVID-19 pandemic
by: Article Editorial
Published: (2020-07-01)

NATIONAL IMMUNIZATION SCHEDULE IMPROVEMENT. RESOLUTION OF THE INDEPENDENT EXPERT COUNCIL IN THE FIELD OF PREVENTIVE IMMUNIZATION
by: article Editorial
Published: (2021-03-01)

Comorbid infections in patients with rheumatoid arthritis
by: B.S. Belov
Published: (2014-05-01)

Efficacy and safety of sarilumab in combination with methotrexate in patients with active rheumatoid arthritis and inadequate effect of methotrexate monotherapy (results of phase III MOBILITY study)
by: E. L. Nasonov, et al.
Published: (2019-05-01)

Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient
by: Fournier M, et al.
Published: (2019-02-01)

EXPERIENCE OF ADMINISTRATION OF HUMAN MONOCLONAL ANTIBODIES TO TNF IN PATIENT WITH JUVENILE RHEUMATOID ARTHRITIS WITH UVEITIS
by: A.O. Lisitsin, et al.
Published: (2009-11-01)

Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors
by: Tanaka T, et al.
Published: (2014-04-01)

EXPERIENCE OF ADMINISTRATION OF HUMAN MONOCLONAL ANTIBODIES TO TNF IN PATIENT WITH JUVENILE RHEUMATOID ARTHRITIS WITH UVEITIS
by: A.O. Lisitsin, et al.
Published: (2009-01-01)

Comorbidities and related factors in rheumatoid arthritis patients of south India- Karnataka Rheumatoid Arthritis Comorbidity (KRAC) study
by: S. Chandrashekara, et al.
Published: (2017-08-01)

RESOLUTION OF THE COUNCIL OF EXPERTS ON «THE PLACE OF PHOSPHODIESTERASE-4 INHIBITOR IN THE COMBINATION TREATMENT OF MODERATE TO SEVERE PSORIASIS AND ACTIVE PSORIATIC ARTHRITIS»
Published: (2017-07-01)

RESOLUTION OF THE COUNCIL OF EXPERTS ON «THE PLACE OF PHOSPHODIESTERASE-4 INHIBITOR IN THE COMBINATION TREATMENT OF MODERATE TO SEVERE PSORIASIS AND ACTIVE PSORIATIC ARTHRITIS»
Published: (2017-01-01)